Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Humans
Middle Aged
Albumins
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Lung Neoplasms
/ drug therapy
Paclitaxel
/ adverse effects
Retrospective Studies
Thymoma
/ drug therapy
Thymus Neoplasms
/ drug therapy
Carboplatin
Efficacy
Nab-paclitaxel
Thymic carcinoma
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
17
05
2022
accepted:
02
01
2023
pubmed:
13
1
2023
medline:
24
3
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
Thymic carcinoma is a very rare neoplasm for which no optimal chemotherapeutic regimen has been established to date. Hence, we performed this study to investigate the efficacy and safety of carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel as a first-line regimen for patients with advanced thymic carcinoma. We conducted this multi-institutional retrospective cohort study of patients with advanced thymic carcinoma who had received carboplatin plus nab-paclitaxel as a first-line chemotherapy between August 2013 and December 2021. Twelve patients were included in this study and were subjected to efficacy and safety analysis. Their median age was 62 years (range, 47-74 years), and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. After a median follow-up time of 19.7 months, the overall response rate was 50%; the median progression-free and overall survival times were 8.8 months and 23.3 months, respectively. Chemotherapy-related peripheral neuropathy was observed in 2 patients (16%; each with grade 1). Other toxicities were manageable, and there were no treatment-related deaths. Carboplatin plus nab-paclitaxel as a first-line chemotherapy regimen showed good efficacy and safety in patients with advanced thymic carcinoma.
Identifiants
pubmed: 36633784
doi: 10.1007/s10637-023-01327-w
pii: 10.1007/s10637-023-01327-w
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-121Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T (2014) Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. BMC Cancer 14:349. https://doi.org/10.1186/1471-2407-14-349
doi: 10.1186/1471-2407-14-349
pubmed: 24885581
pmcid: 4039543
Nakajima J, Okumura M, Yano M, Date H, Onuki T, Haniuda M, Sano Y, Japanese Association for Research of Thymus (2016) Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database. Eur J Cardiothorac Surg 49:1510–1515. https://doi.org/10.1093/ejcts/ezv380
doi: 10.1093/ejcts/ezv380
pubmed: 26537756
Kondo K, Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76:878–885. https://doi.org/10.1016/s0003-4975(03)00555-1
doi: 10.1016/s0003-4975(03)00555-1
pubmed: 12963221
Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF (2013) Thymic carcinoma: A multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 95:299–303. https://doi.org/10.1016/j.athoracsur.2012.09.006
doi: 10.1016/j.athoracsur.2012.09.006
pubmed: 23141529
Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, Koja K, Kinjo T, Adachi G, Murayama S (2002) Treatment and prognosis of thymic carcinoma: A retrospective analysis of 40 cases. Cancer 94:3115–3119. https://doi.org/10.1002/cncr.10588
doi: 10.1002/cncr.10588
pubmed: 12115342
Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, Endo M, Yamamoto N (2010) Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 67:194–197. https://doi.org/10.1016/j.lungcan.2009.03.031
doi: 10.1016/j.lungcan.2009.03.031
pubmed: 19409644
Furugen M, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T (2011) Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol 41:1013–1016. https://doi.org/10.1093/jjco/hyr089
doi: 10.1093/jjco/hyr089
pubmed: 21742653
Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065. https://doi.org/10.1200/jco.2010.32.9607
doi: 10.1200/jco.2010.32.9607
pubmed: 21502559
pmcid: 3107762
Hirai F, Yamanaka T, Taguchi K et al (2015) A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 26:363–368. https://doi.org/10.1093/annonc/mdu541
doi: 10.1093/annonc/mdu541
pubmed: 25403584
Ettinger DS, Riely GJ, Akerley W et al (2013) Thymomas and thymic carcinomas: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 11:562–576. https://doi.org/10.6004/jnccn.2013.0072
doi: 10.6004/jnccn.2013.0072
pubmed: 23667206
Koizumi W, Morita S, Sakata Y (2015) A randomized phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol 45:303–306. https://doi.org/10.1093/jjco/hyu205
doi: 10.1093/jjco/hyu205
pubmed: 25516635
Chirgwin J, Chua SL (2011) Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review. Breast 20:394–406. https://doi.org/10.1016/j.breast.2011.06.004
doi: 10.1016/j.breast.2011.06.004
pubmed: 21839635
Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324. https://doi.org/10.1158/1078-0432.ccr-05-1634
doi: 10.1158/1078-0432.ccr-05-1634
pubmed: 16489089
Makimoto G, Fujiwara K, Watanabe H, Kameyama N, Matsushita M, Rai K, Sato K, Yonei T, Sato T, Shibayama T (2014) nab-Paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. Case Rep Oncol 7:14–17. https://doi.org/10.1159/000357938
doi: 10.1159/000357938
pubmed: 24575009
pmcid: 3934614
Araya T, Kita T, Matsuoka H, Sakai T, Kimura H, Kasahara K (2020) Successful treatment of advanced thymic carcinoma with carboplatin plus nab-paclitaxel and maintenance monotherapy with nab-paclitaxel: Two case reports. Case Rep Oncol 13:1506–1512. https://doi.org/10.1159/000510894
doi: 10.1159/000510894
pubmed: 33564291
pmcid: 7841741
Funaishi K, Yamasaki M, Saito N, Daido W, Ishiyama S, Deguchi N, Taniwaki M, Ohashi N (2017) First-line treatment with carboplatin plus nab-paclitaxel and maintenance monotherapy with nab-paclitaxel for a thymic carcinoma: A case report. Case Rep Oncol 10:571–576. https://doi.org/10.1159/000477758
doi: 10.1159/000477758
pubmed: 28868014
pmcid: 5567109
Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492. https://doi.org/10.1002/1097-0142(19811201)48:11%3C2485::aid-cncr2820481123%3E3.0.co;2-r
doi: 10.1002/1097-0142(19811201)48:11%3C2485::aid-cncr2820481123%3E3.0.co;2-r
pubmed: 7296496
Agatsuma T, Koizumi T, Kanda S, Ito M, Urushihata K, Yamamoto H, Hanaoka M, Kubo K (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6:2130–2134. https://doi.org/10.1097/jto.0b013e31822e71c0
doi: 10.1097/jto.0b013e31822e71c0
pubmed: 21892103
Song Z, Yu X, Zhang Y (2015) Chemotherapy and prognosis in advanced thymic carcinoma patients. Clinics 70:775–780. https://doi.org/10.6061/clinics/2015(12)03
doi: 10.6061/clinics/2015(12)03
pubmed: 26735216
pmcid: 4676312
Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M, Nishiwaki Y (2003) Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is effective treatment for advanced thymic carcinoma. Cancer 98:926–931. https://doi.org/10.1002/cncr.11606
doi: 10.1002/cncr.11606
pubmed: 12942558
Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M (2011) Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: Evaluation of efficacy and toxicity. Lung Cancer 74:492–496. https://doi.org/10.1016/j.lungcan.2011.05.013
doi: 10.1016/j.lungcan.2011.05.013
pubmed: 21665316
Inoue A, Sugawara S, Harada M et al (2014) Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer Group Study 0803. J Thorac Oncol 9:1805–1809. https://doi.org/10.1097/jto.0000000000000362
doi: 10.1097/jto.0000000000000362
pubmed: 25393793
Luo Y, Li JL, Yang L, Zhang W (2016) Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity. Thoracic Cancer 7:167–172. https://doi.org/10.1111/1759-7714.12300
doi: 10.1111/1759-7714.12300
pubmed: 27042218
Ko R, Shukuya T, Okuma Y, Tateishi K et al (2018) Prognostic factors and efficacy of first-line chemotherapy in patients with advanced thymic carcinoma: A retrospective analysis of 286 patients from NEJ023 study. Oncologist 23:1210–1217. https://doi.org/10.1634/theoncologist.2017-0586
doi: 10.1634/theoncologist.2017-0586
pubmed: 29567820
pmcid: 6263125
Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 30:2055–2062. https://doi.org/10.1200/jco.2011.39.5848
doi: 10.1200/jco.2011.39.5848
pubmed: 22547591
Takeishi K, Ko R, Shukuya T et al (2020) Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 191 patients from the NEJ023 study. Oncologist 25:e684–e690. https://doi.org/10.1634/theoncologist.2019-0593
doi: 10.1634/theoncologist.2019-0593
Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630. https://doi.org/10.1056/nejmoa1406470
doi: 10.1056/nejmoa1406470
pubmed: 25671254
Ikeda K, Kudo M, Kawazoe S et al (2017) Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 52:512–519. https://doi.org/10.1007/s00535-016-1263-4
doi: 10.1007/s00535-016-1263-4
pubmed: 27704266
Sato J, Satouchi M, Itoh S et al (2020) Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21:843–850. https://doi.org/10.1016/s1470-2045(20)30162-5
doi: 10.1016/s1470-2045(20)30162-5
pubmed: 32502444